Julia Prater1, Fabio Valeri1,2, Dimitri Korol1, Sabine Rohrmann3, Silvia Dehler1. 1. Cancer Registry Zurich and Zug, Zurich, Switzerland. 2. Institute of Primary Care, University of Zurich, University Hospital of Zurich, Zurich, Switzerland. 3. Division of Chronic Disease Epidemiology; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland. sabine.rohrmann@uzh.ch.
Abstract
PURPOSE: To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland. METHODS: For 1980-2006, patients with unilateral invasive breast cancer (UBC) were analysed for metachronous CBC. Poisson's regression was used to estimate incidence rates of metachronous CBC according to age, year of diagnosis, follow-up period since first breast cancer and morphology. RESULTS: Of 16,323 patients with UBC, 700 (4.3%) developed a second malignant tumour of the opposite breast. Median age at first breast cancer was lower in the CBC group than in the full cohort. Median interval time between first and second breast cancer was 5.5 (interquartile range 2.6-10.1) years. Incidence rate at age 20-29 was 1006 (95% confidence interval, CI, 452-2238) cases per 100,000 person-years and decreased to 299 (199-450) at 80-84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 (530-721) for 1980-1984 to 329 (217-500) cases per 100,000 person-years for 2005-2006. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95% CI 0.99-1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma. CONCLUSIONS: In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma were associated with an increased risk of CBC.
PURPOSE: To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland. METHODS: For 1980-2006, patients with unilateral invasive breast cancer (UBC) were analysed for metachronous CBC. Poisson's regression was used to estimate incidence rates of metachronous CBC according to age, year of diagnosis, follow-up period since first breast cancer and morphology. RESULTS: Of 16,323 patients with UBC, 700 (4.3%) developed a second malignant tumour of the opposite breast. Median age at first breast cancer was lower in the CBC group than in the full cohort. Median interval time between first and second breast cancer was 5.5 (interquartile range 2.6-10.1) years. Incidence rate at age 20-29 was 1006 (95% confidence interval, CI, 452-2238) cases per 100,000 person-years and decreased to 299 (199-450) at 80-84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 (530-721) for 1980-1984 to 329 (217-500) cases per 100,000 person-years for 2005-2006. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95% CI 0.99-1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma. CONCLUSIONS: In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma were associated with an increased risk of CBC.
Entities:
Keywords:
Follow-up period; Incidence rates; Lobular carcinoma; Metachronous contralateral breast cancer; Year of diagnosis
Authors: Voralak Vichapat; Hans Garmo; Lars Holmberg; Ian S Fentiman; Andrew Tutt; Cheryl Gillett; Margreet Lüchtenborg Journal: Breast Cancer Res Treat Date: 2011-06-14 Impact factor: 4.872
Authors: Helena M Verkooijen; Vanessa Chatelain; Gérald Fioretta; Georges Vlastos; Elisabetta Rapiti; André-Pascal Sappino; Christine Bouchardy; Pierre O Chappuis Journal: Breast Cancer Res Treat Date: 2006-12-21 Impact factor: 4.872
Authors: Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: L E Rutqvist; B Cedermark; U Glas; A Mattsson; L Skoog; A Somell; T Theve; N Wilking; J Askergren; M L Hjalmar Journal: J Natl Cancer Inst Date: 1991-09-18 Impact factor: 13.506
Authors: A Font-Gonzalez; L Liu; A C Voogd; M K Schmidt; J A Roukema; J W W Coebergh; E de Vries; I Soerjomataram Journal: Breast Cancer Res Treat Date: 2013-06-13 Impact factor: 4.872
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Maria E C Sandberg; Per Hall; Mikael Hartman; Anna L V Johansson; Sandra Eloranta; Alexander Ploner; Kamila Czene Journal: PLoS One Date: 2012-10-08 Impact factor: 3.240
Authors: Daniele Giardiello; Iris Kramer; Maartje J Hooning; Michael Hauptmann; Esther H Lips; Elinor Sawyer; Alastair M Thompson; Linda de Munck; Sabine Siesling; Jelle Wesseling; Ewout W Steyerberg; Marjanka K Schmidt Journal: NPJ Breast Cancer Date: 2020-11-03